Literature DB >> 11521798

Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease.

M Raderer1, C Osterreicher, K Machold, M Formanek, W Fiebiger, M Penz, B Dragosics, A Chott.   

Abstract

BACKGROUND AND AIMS: Gastric MALT-lymphoma is thought to be related to chronic antigenic stimulation provided by Helicobacter pylori (HP). As clonal expansion of gastric B cells not related to HP has been demonstrated in patients with autoimmune disease (AD), we have analysed whether AD adversely influences response of MALT-lymphoma following HP-eradication. PATIENTS AND METHODS: Retrospective analysis of all patients with early stage gastric MALT-lymphoma treated with HP-eradication was performed. The presence of AD was evaluated by personal questioning for specific symptoms and serologically by analysis of rheumatoid factor, antinuclear antibodies and thyroid autoantibodies.
RESULTS: A total of 22 patients were identified receiving only antibiotic treatment for initial management, and six presented with an autoimmune condition: three had Sjögren's syndrome, one polymyalgia rheumatica, one autoimmune thyroiditis along with psoriasis, and one patient had only autoimmune thyroiditis. Successful eradication of HP was achieved in all patients, and 15 of 22 patients (68%) achieved complete response of the lymphoma, while none out of the six patients with an autoimmune disorder responded to HP-eradication.
CONCLUSION: Apart from questioning the role of HP in the development of lymphoma in such patients, these results suggest that patients with autoimmune disease might not be optimal candidates for HP-eradication even in case of early stage lymphoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521798     DOI: 10.1023/a:1011122904602

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

1.  Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas.

Authors:  M Raderer; B Streubel; S Wöhrer; M Häfner; A Chott
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

Review 2.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  Renal involvement in primary Sjögren's syndrome: a clinicopathologic study.

Authors:  Saugar Maripuri; Joseph P Grande; Thomas G Osborn; Fernando C Fervenza; Eric L Matteson; James V Donadio; Marie C Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-13       Impact factor: 8.237

Review 4.  Sjögren's syndrome: diagnosis and therapeutic challenges in the elderly.

Authors:  Kristine P Ng; David A Isenberg
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Helicobacter pylori infection and endocrine disorders: is there a link?

Authors:  Konstantinos X Papamichael; Garyphallia Papaioannou; Helen Karga; Anastasios Roussos; Gerassimos J Mantzaris
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

Review 6.  Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Andriani; Francesca Cristofari; Chiara Bassanelli; Gian Paolo Spinelli; Silverio Tomao; Sergio Morini
Journal:  Med Oncol       Date:  2009-03-24       Impact factor: 3.064

7.  Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution.

Authors:  Francesca Collina; Anna De Chiara; Amalia De Renzo; Gaetano De Rosa; Gerardo Botti; Renato Franco
Journal:  Infect Agent Cancer       Date:  2012-04-02       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.